The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
The prevalence of HLA-B*57 serotype associated with hypersensitivity reactions in the treatment of HIV infection in the Turkish population
CONCLUSION: Considering these results, it can be assumed that the prevalence of HLA-B*57:01 in Turkey is lower than 3.3%. Instead of a high-resolution HLA-B*57:01 scan in all patients starting abacavir therapy, a high-resolution HLA-B*57:01 scan might be of greater benefit in patients who are positive on a low-resolution HLA-B*57 scan.PMID:37526185 | DOI:10.2174/1570162X21666230731145350 (Source: Current HIV Research)
Source: Current HIV Research - August 1, 2023 Category: Infectious Diseases Authors: Muhammed Ali Kizmaz Abdurrahman Simsek Figen Aymak E Halis Akalin H Barbaros Oral Ferah Budak Source Type: research
Milestones: Dr. Robert C. Gallo and the Discovery of HIV-1
Curr HIV Res. 2023;21(1):2-5. doi: 10.2174/1570162X2101230327090914.NO ABSTRACTPMID:37493081 | DOI:10.2174/1570162X2101230327090914 (Source: Current HIV Research)
Source: Current HIV Research - July 26, 2023 Category: Infectious Diseases Authors: Paolo Lusso Source Type: research
Milestones: Dr. Robert C. Gallo and the Discovery of HIV-1
Curr HIV Res. 2023;21(1):2-5. doi: 10.2174/1570162X2101230327090914.NO ABSTRACTPMID:37493081 | DOI:10.2174/1570162X2101230327090914 (Source: Current HIV Research)
Source: Current HIV Research - July 26, 2023 Category: Infectious Diseases Authors: Paolo Lusso Source Type: research
